System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Gaëlle Quereux is an expert in Dermatology at Centre Hospitalier Universitaire de Nantes (France). As of October 2026, ScienceLeadR ranks Gaëlle Quereux in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Gaëlle Quereux has authored 411 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 9 of them ongoing. SLR score: 1,315 (community average: 125). How the SLR is computed.

LeadR Profile

Gaëlle Quereux Centre Hospitalier Universitaire de Nantes France
1 315 ScienceLeadR Reputation 1315

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Biochemistry - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Centre d'Investigation Clinique de Nantes

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 411

Citations

Citations: 4 605 1st author: 40 Last author: 48 Unique author: 1

Main journals

Ann Dermatol Venereol 139
Annales de Dermatologie et de Vénéréologie - FMC 35
Annales de dermatologie et de vénéréologie, FMC 20
J Eur Acad Dermatol Venereol 19
Br J Dermatol 16

Best Journals

Ann Oncol 6
J Clin Oncol 5
Nat Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Inflammatory rheumatic diseases under mogamulizumab: a multicenter series of 11 cases.
PMID 42858804 — lymphoma, adrenal cortex hormones, arthritis, rheumatic diseases, therapeutics, methotrexate		Joint Bone Spine20260
Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery.
PMID 42770835 — language, melanoma, nivolumab		Future Oncol20260
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
PMID 42667537 — safety, melanoma, nivolumab, therapeutics		Dermatol Ther (Heidelb)20260
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
PMID 42501621 — safety, melanoma, neoplasms, therapeutics, mutation		Eur J Cancer20260
Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.
PMID 42490360 — syphilis, sezary syndrome, dermatology		Br J Dermatol20260

Clinical Studies 34

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Chair: 1 Study Director: 1

By phase:

Phase 3 16
N/A 9
Phase 2 4
Phase 1/Phase 2 2
Phase 1 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 10
Recruiting 10
Active not recruiting 5
Terminated 4
Unknown 4
Not yet recruiting 1

By type:

Interventional 27
Observational 7

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 0
multicentric5to9 1
multicentricup10 25

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
Prophylaxis of Recurrent Erysipelas in Lower Limbs compreSsion thErapy vs aNTibiotics and Compression Therapy
NCT07549594 — nurses, research design, cellulitis, telemedicine, emollients, erysipelas, penicillin v, therapeutics, random allocation, infections, stockings, compression, male		Phase 4Not yet recruiting2026
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence
NCT06692556 — radiotherapy, skin, cells, carcinoma, squamous cell, brachytherapy, neoplasms, radiotherapy, adjuvant, beds, therapeutics, nervous system, carcinoma, cutaneous squamous cell carcinoma		Phase 3Recruiting2025
DEprescribing Perceptions of PAtients Living With Advanced Cancer
NCT06193083 — exercise, quality of life, polypharmacy, language, reading, communication, neoplasms, writing, perception, social skills, deprescriptions, therapeutics, palliative care, health literacy, functional status, literacy		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS